Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Gerresheimer    GXI   DE000A0LD6E6

GERRESHEIMER (GXI)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Gerresheimer : expands its training offering in the Czech Republic

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/30/2018 | 04:43pm CEST

The close partnership with the vocational school in Domažlice means that the apprentices are given the best possible theoretical and practical preparation for their exams. In František Toman, the plant has its own 'trainer' for the apprentices, someone for them to turn to if they have any questions. In 2015, he was named 'trainer for professional training' by the Czech Ministry of Education and Ministry of Industry and Trade.

In around three years, all three apprentices will have completed their training and will be part of the factory team at Horšovský Týn.

The company is also committed to protecting the environment and supports social organizations that, for instance, make it easier for disabled people to find their first job.

The Gerresheimer Group's Czech site mainly makes asthma inhalers for well-known pharmaceutical companies. The plant's 700 or so employees guarantee the highest possible quality in all production steps and processes. To this end, it boasts a total of 15,000 square meters of clean room space in ISO classes 8 and 9.

More information

Gerresheimer Plastics & Devices

About Gerresheimer

Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contributes to health and well-being. Gerresheimer operates worldwide and its approximately 10,000 employees manufacture products in local markets, close to its customers. With our plants in Europe, North America, South America, and Asia, we generate revenues of approximately EUR 1.4 billion. The company's comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: insulin pens, inhalers, prefillable syringes, injection vials, ampoules, bottles, and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.

Disclaimer

Gerresheimer AG published this content on 30 May 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 30 May 2018 14:42:03 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GERRESHEIMER
09/21GERRESHEIMER : A great start to professional life
PU
09/19GERRESHEIMER AT CPHI WORLDWIDE : Gerresheimer to expand its services to include ..
PU
09/17GERRESHEIMER AT LUXEPACK 2018 : Gerresheimer’s new Decoration Center
PU
09/14GERRESHEIMER : Series production of Gx RTF ClearJect plastic syringes started
PU
09/12GERRESHEIMER AG : Release according to Article 40, Section 1 of the WpHG [the Ge..
EQ
09/12GERRESHEIMER AG : Release according to Article 40, Section 1 of the WpHG [the Ge..
EQ
09/12GERRESHEIMER : and Sensile Medical to attend CPhI Worldwide together for the fir..
PU
09/10GX® INNOSAFE : Greater protection against needle stick injuries
PU
09/10GERRESHEIMER : Dietmar Siemssen appointed new CEO of Gerresheimer AG
AQ
09/06GERRESHEIMER AG : Dietmar Siemssen appointed new CEO of Gerresheimer AG
EQ
More news
News from SeekingAlpha
04/13Gerresheimer AG ADR 2018 Q1 - Results - Earnings Call Slides 
02/23Gerresheimer AG ADR 2017 Q4 - Results - Earnings Call Slides 
2017Gerresheimer AG ADR 2017 Q3 - Results - Earnings Call Slides 
2015Corning buying German pharma glass tubing business for $219m 
Financials (€)
Sales 2018 1 370 M
EBIT 2018 162 M
Net income 2018 118 M
Debt 2018 828 M
Yield 2018 1,72%
P/E ratio 2018 18,30
P/E ratio 2019 24,77
EV / Sales 2018 2,24x
EV / Sales 2019 2,14x
Capitalization 2 240 M
Chart GERRESHEIMER
Duration : Period :
Gerresheimer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GERRESHEIMER
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 75,7 €
Spread / Average Target 6,1%
EPS Revisions
Managers
NameTitle
Axel Herberg Chairman-Supervisory Board
Rainer Beaujean Chief Financial Officer
Theodor Stuth Independent Member-Supervisory Board
Udo J. Vetter Independent Member-Supervisory Board
Francesco Grioli Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
GERRESHEIMER2.72%2 635
MEDTRONIC PLC21.18%133 512
BAXTER INTERNATIONAL19.83%41 539
ALIGN TECHNOLOGY76.87%31 241
ZIMMER BIOMET HOLDINGS8.15%26 705
TERUMO CORP22.12%22 497